4
Changes in Ownership
Sionna Therapeutics, Inc. Filed Acc 0001704336-25-000004
President & CEO sold 25,000 shares at an average $29.11 ($727,798)
- President & CEO acquired 25,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Cloonan Michael President & CEO | 2025-09-26 | Option exercise 10b5-1 | +17,207 | $6.11 | $105,135 | 564,550 | D: show line 1 in the form |
| Cloonan Michael President & CEO | 2025-09-26 | Sale 10b5-1 | −17,207 | $28.85 | $496,346 | 547,343 | D: show line 2 in the form |
| Cloonan Michael President & CEO | 2025-09-29 | Option exercise 10b5-1 | +7,793 | $6.11 | $47,615 | 555,136 | D: show line 3 in the form |
| Cloonan Michael President & CEO | 2025-09-29 | Sale 10b5-1 | −7,793 | $29.70 | $231,451 | 547,343 | D: show line 4 in the form |
| Open-market sales · 25,000 sh · avg $29.11 · $727,798 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Cloonan Michael President & CEO | 2025-09-26 | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −17,207 | 185,935 | D: show line 5 in the form | |||||
| Cloonan Michael President & CEO | 2025-09-29 | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −7,793 | 178,142 | D: show line 6 in the form |
Loading xslF345X05/edgardoc.xml…